Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.10. rezultāts no 100.
514. lappuse
... crystallinity , nafcillin content , and identity . ( ii ) Samples required : ( a ) For all tests except sterility : 10 packages , each containing approxi- mately 300 milligrams . ( b ) For sterility testing : 20 packages , each ...
... crystallinity , nafcillin content , and identity . ( ii ) Samples required : ( a ) For all tests except sterility : 10 packages , each containing approxi- mately 300 milligrams . ( b ) For sterility testing : 20 packages , each ...
515. lappuse
... crystallinity , and identity . ( ii ) Samples required : 10 packages , each containing approximately 300 mil- ligrams . ( b ) Tests and methods of assay ( 1 ) Po- tency . Assay for potency by any of the following methods ; however ...
... crystallinity , and identity . ( ii ) Samples required : 10 packages , each containing approximately 300 mil- ligrams . ( b ) Tests and methods of assay ( 1 ) Po- tency . Assay for potency by any of the following methods ; however ...
517. lappuse
... crystallinity . ( ii ) Samples required : ( a ) For all tests except sterility : 10 packages , each containing approxi- mately 300 milligrams . ( b ) For sterility testing : 20 packages , each containing approximately 600 mil- ligrams ...
... crystallinity . ( ii ) Samples required : ( a ) For all tests except sterility : 10 packages , each containing approxi- mately 300 milligrams . ( b ) For sterility testing : 20 packages , each containing approximately 600 mil- ligrams ...
518. lappuse
... crystallinity . ( ii ) Samples required : 10 packages , each containing approximately 300 mil- ligrams . ( b ) Tests and methods of assay ( 1 ) Po- tency . Assay for potency by any of the following methods ; however , the re- sults ...
... crystallinity . ( ii ) Samples required : 10 packages , each containing approximately 300 mil- ligrams . ( b ) Tests and methods of assay ( 1 ) Po- tency . Assay for potency by any of the following methods ; however , the re- sults ...
519. lappuse
... Crystallinity . Proceed as directed in § 436.203 ( a ) of this chapter . [ 42 FR 59859 , Nov. 22 , 1977 , as amended at 50 FR 19918 , 19919 , May 13 , 1985 ] - · - § 440.74a Sterile penicillin G procaine . ( a ) Requirements for ...
... Crystallinity . Proceed as directed in § 436.203 ( a ) of this chapter . [ 42 FR 59859 , Nov. 22 , 1977 , as amended at 50 FR 19918 , 19919 , May 13 , 1985 ] - · - § 440.74a Sterile penicillin G procaine . ( a ) Requirements for ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning